NCT03419559撤回2 期
A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combination With Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 8
- 主要终点
- ≥ Grade 3 Treatment-Emergent Adverse Event
研究概览
简要总结
This study is a Phase 2, open-label, multicenter study evaluating adoptive cell therapy (ACT) with autologous TIL therapy (LN-145) in combination with Anti-PD-L1 inhibitor durvalumab.
详细描述
LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI. The cell transfer therapy used in this study involves patients receiving a nonmyeloablative (NMA) lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of Stage III or Stage IV NSCLC and progressed after ≤ 3 lines of prior systemic therapy in the locally advanced or metastatic setting
- •Have at least 1 lesion resectable for TIL generation
- •Measurable disease as defined by RECIST v1.1
- •Male or female, ≥ 18 years of age
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and estimated life expectancy of ≥ 3 months
- •Adequate bone marrow function at screening
- •Adequate organ function at screening
- •A washout period from prior anticancer therapy(ies) of a minimum duration is required prior to first study treatment
- •Recovered from all prior anticancer therapy-related AEs to Grade 1 or less (per CTCAE v4.03) prior to enrollment
- •Female patients of childbearing potential and male patients with partners of childbearing potential patient must agree to use contraception while on study and during the timeframes as specified following the last dose of study drug(s) received, or until the first dose of the subsequent anticancer therapy, whichever is longer
- •Evidence of postmenopausal status or negative urine or serum pregnancy test for female premenopausal patients
排除标准
- •History of other malignancies, except for the following: adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, curatively-treated thyroid cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3 years
- •Patients who have received prior cell therapy
- •Patients who have received prior checkpoint inhibitors: such as anti-PD-1, anti-PD-L1 inhibitors, and durvalumab
- •Active or prior documented autoimmune or inflammatory disorders
- •History of primary or acquired immunodeficiency syndrome, history of allogeneic organ transplant that requires therapeutic immunosuppression
- •Received live or attenuated vaccination within 28 days prior to the start of NMA-LD
- •Patients with a history of hypersensitivity to any component of the study drugs
- •Mean QT interval ≥ 470 msec
- •Patients who have a left ventricular ejection fraction (LVEF) of < 45% or who are New York Heart Association (NYHA) Class 2 or higher
- •Serious illnesses or medical conditions, which would pose increased risk for study participation and/or compliance with the protocol
- •Patients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of ≤ 60%
- •Active central nervous system metastases and/or leptomeningeal disease
- •Female patients who are pregnant or breastfeeding
- •Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or HIV
- •Current or prior use of immunosuppressive medication within 28 days before the first dose of study treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
研究组 & 干预措施
LN-145 in combination with durvalumab
Experimental
After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
干预措施: LN-145 (Biological)
LN-145 in combination with durvalumab
Experimental
After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
干预措施: Durvalumab (Drug)
结局指标
主要结局
≥ Grade 3 Treatment-Emergent Adverse Event
时间窗: A maximum of 24 months
To evaluate the safety as measured by any ≥ Grade 3 treatment-emergent adverse event (TEAE) rate
Objective Response Rate
时间窗: A maximum of 24 months
To evaluate efficacy using the objective response rate (ORR)
次要结局
- Overall Survival(A minimum of 5 years)
- Duration of Response(A maximum of 24 months)
- Progression Free Survival(A maximum of 24 months)
研究者
研究点 (8)
Loading locations...
相似试验
终止
2 期
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaCervical CarcinomaNCT03108495Iovance Biotherapeutics, Inc.210
已完成
2 期
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaMetastatic MelanomaNCT02360579Iovance Biotherapeutics, Inc.220
招募中
2 期
TIL Therapy in Non-small-cell Lung Cancer (NSCLC) PatientsNon-Small Cell Lung CancerNCT06455917University Hospital, Basel, Switzerland30
进行中（未招募）
2 期
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaNCT06423885Sichuan Baili Pharmaceutical Co., Ltd.64
已完成
2 期
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia (B-CLL)NCT00328198Genzyme, a Sanofi Company86